Results for Drug Targets

Dr. John studies metabolism in the setting of pediatric infections, in order to identify new anti-infective drug targets, understand drug resistance, and develop new diagnostics.

Dr. Diskin's research is focused on translational genomics in childhood cancers. Her laboratory seeks to identify the genetic basis of childhood cancers by combining quantitative computational methods with rigorous "wet-lab" experimental approaches. In parallel, she has developed, and is applying, a proteogenomic approach to identify novel immunotherapeutic targets for high-risk and relapsed pediatric malignancies.

Dr. Snyder is a pediatric hematologist oncologist focused on improving the lives of people living with vascular anomalies. She is involved with national and international endeavors to create educational programs and investigational registries, investigate treatments, and author publications in this discipline.

The research interests of Dr. Downes focus on antimicrobial clinical pharmacology and pharmacoepidemiology in children with a goal to identify novel approaches to optimize efficacy, minimize toxicity, and limit antimicrobial resistance from antibiotics.

The cure rate for children with neuroblastoma is unacceptable, making it imperative that new therapies are developed. Dr. Bosse's laboratory is focused on discovering and developing new neuroblastoma cell surface immunotherapeutic targets. Along with his colleagues, Dr. Bosse's aim is to capitalize on the robust differential expression of these molecules with immune-based therapies and also define their mechanisms of overexpression and roles in tumorigenesis.

Dr. Gonzalez-Alegre's long-range research goal is to advance the application of precision medicine in the neurology clinic. His research focus revolves around genetic disorders that affect the brain, spanning from the diagnosis of novel genetic disease in the clinic to the identification of novel molecular targets using disease models and the design of early-phase human clinical trials.